Zhitong Finance App News, Pharmaceutical Juno-B (02126) announced that the JW contracting party (Company and JWS) signed a license and transfer agreement with Eureka Contractor (Eureka Cayman) and Eureka Hong Kong on November 9, 2026 (after the trading period). Accordingly, JWS transferred all of its rights, title and interest in the transferred assets (including Eureka's license) to Eureko Hong Kong, and granted each JW contracting party an exclusive charging license for Eureko Hong Kong's licensed assets within the region In the field, products are used in exchange for the total cost.
As part of the price of the transfer of assets by JWS and the licensing of the licensed assets by the JW Contractor, Eureko Hong Kong (or Eureko's Hong Kong affiliate designated in writing) must pay the JW Contractor a non-refundable, non-deductible and irrevocable one-time advance payment of $10 million on or before the effective date. Assuming that Eureko Group enters into a transaction within the qualifying period and that Eureko Group achieves all three net sales targets within the milestone period, the total amount of commercial milestone payments will not exceed $100 million.
Eureko licenses form the basis for the company's four candidate products to be used to treat solid tumors: JWATM203, an autologous TCR-like T-cell therapy targeting AFP; JWATM213, a candidate product combining JWATM203 with independent technology (related to T-cell anti-depletion function) introduced by the company from Lyell; JWATM204, an autologous TCR T-cell therapy targeting GPC3 to treat hepatocellular carcinoma; and JWATM214, a combination of jWATM204 and from Lyell A candidate product for the introduced technology.
Considering its strategic goal of streamlining R&D plans, as well as the development progress of JWCAR201 and JWCAR239 and the strategic and commercial value expected to be generated by the Group's FAST production platform, the company decided to prioritize R&D expenditure on projects and platforms with clear clinical trials, clear development prospects, and potential commercial benefits, such as JWCAR201, JWCAR239, and Relma-cel (as second-line treatment for LBCL). The company has also used its existing lentivirus vector, process development and production capacity to prioritize the development of its self-developed in-vivo cell therapy platform. Therefore, the board of directors has determined that it is more in the company's interest to transfer the transferred assets (including Eureko licenses) to Eureko, license the assets to Eureko, and use the proceeds of the transaction for research and development of the pipeline section that has been assigned a higher priority.